Portal
Portal Biotechnologies is a life sciences company that develops cell engineering and cell analytics solutions for research and clinical applications. The company's proprietary membrane technology uses mechanical disruption (mechanoporation) to enable massive parallelization of intracellular delivery, facilitating the delivery of RNA, gene editing tools, and other molecular cargos into cells. Portal's product suite…
Funding snapshot
About
Portal Biotechnologies is a life sciences company that develops cell engineering and cell analytics solutions for research and clinical applications. The company's proprietary membrane technology uses mechanical disruption (mechanoporation) to enable massive parallelization of intracellular delivery, facilitating the delivery of RNA, gene editing tools, and other molecular cargos into cells. Portal's product suite includes the Gateway, Galaxy, Millibooster, and Galaxy-i platforms, which support multiplexed cargo delivery for drug discovery, cell therapy manufacturing, and AI data generation. The company has secured over 100 customers including 7 of the top 10 pharmaceutical companies and has been awarded an $8M DARPA contract to develop a portable red blood cell engineering device for rapid point-of-care production and treatment. Portal's technology has been validated in peer-reviewed publications including Frontiers in Immunology and the Journal of Immunology. Founded in 2023 and headquartered in Watertown, Massachusetts, Portal has raised $25.7M in Seed funding from investors including Pear VC, Conscience VC, IA Ventures, NFX, 10X Capital, and TechU.
Business model
Genomics > Enabling Technologies > Technology Platforms > Gene Delivery
Team background
College Wise > Massachusetts Institute of Technology, Stanford University
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.